beneficiaries discharged alive from an acute care hospital between January 2000 and December 2015 (n = 199 069 327), excluding discharges younger than 65 years or discharged to hospice (n = 39 036 324 or 19.6%), enrolled in Medicare Advantage (n = 20 250 852 or 10.2%), or discharged to institutional settings other than SNF or IRF (eg, psychiatric hospital; n = 1 808 518 or 0.9%). We identified each discharge's first posthospitalization destination (home vs institutional post-acute care) and the number of days in the hospital and post-acute care. We used multivariable regression to predict riskadjusted annual outcomes adjusted for age, sex, race, and 31 Elixhauser comorbidities. We tested for the statistical significance of differences over time using t tests (2-tailed with an α of .05). All analyses were performed using Stata (StataCorp), version 15. This study was approved by the institutional review board of the University of Pennsylvania with a waiver of informed consent.
Results | Among 137 973 633 hospital discharges, 20.3% were discharged to SNFs and 3.7% were discharged to IRFs. Discussion | The use of institutional post-acute care increased between 2000 and 2015 and was accompanied by increasing length of post-acute care stays through 2014. These trends did not appear to change when payment reform was implemented under the Affordable Care Act. SNFs (which accounted for 85% of institutional post-acute care) are paid per diem and thus may have strong incentives to maintain longer lengths of stay. This study was limited by the exclusion of Medicare Advantage enrollees. If policy incentives are to effectively reduce SNF length of stay, they might need to align SNF payment with the goal of reducing SNF use.
It is uncertain whether the use of post-acute care benefits patients. Despite its proliferation, there is little evidence that post-acute care improves key patient outcomespreventing rehospitalizations or improving functional recovery. Further investigating how post-acute care affects patient outcomes is essential.
Rachel M. Werner, MD, PhD R. Tamara Konetzka, PhD 
COMMENT & RESPONSE

Diagnosis and Treatment of Hidradenitis Suppurativa
To the Editor Drs Saunte and Jemec performed an illustrative review focused on the advances in diagnosis and treatment of hidradenitis suppurativa (HS). 1 However, the advances in imaging of the disease were not discussed. For example, regarding the pathogenesis, ultrasound studies have allowed visualization of the hidden connections between the tunnels or fistulous tracts and fluid collections and the dilated and ruptured base of the hair follicles, which were illustrated in Figure 3 in the article.
1-3
Regarding the staging of hidradenitis, ultrasonography has also demonstrated that clinical evaluation and commonly used clinical scoring systems can miscategorize as healthy skin corporal segments with fluid collections or fistulous tracts underneath.
3 The latter findings on imaging can be critical because, as pointed out by the authors, the choice of therapy is guided by disease severity. Currently, color Doppler ultrasound can support the detection of key subclinical lesions, the staging of the disease, and the assessment of activity and has been added to the clinical evaluation of hidradenitis in many centers around the world. 3,4 Moreover, ultrasound is also being used in ongoing trials. In patients with indications for local or systemic treatments, imaging can be a noninvasive tool for monitoring the response. In patients with a surgical indication, an imageguided mapping of the extent of the abnormalities can be performed. Ultrasound has the ability to detect, categorize, and measure the lesions in all the corporal regions affected by hidradenitis.
3 This imaging information may allow better selection of the type of medical treatment or the location and extent of the surgical incision. 
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